1. Home
  2. SFST vs ARVN Comparison

SFST vs ARVN Comparison

Compare SFST & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Southern First Bancshares Inc.

SFST

Southern First Bancshares Inc.

HOLD

Current Price

$60.76

Market Cap

578.6M

Sector

Finance

ML Signal

HOLD

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$8.35

Market Cap

516.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SFST
ARVN
Founded
1999
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
578.6M
516.2M
IPO Year
2012
2018

Fundamental Metrics

Financial Performance
Metric
SFST
ARVN
Price
$60.76
$8.35
Analyst Decision
Buy
Buy
Analyst Count
1
19
Target Price
$64.00
$15.05
AVG Volume (30 Days)
145.6K
724.1K
Earning Date
04-21-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
94.76
58.84
EPS
1.19
N/A
Revenue
$6,282,000.00
$262,600,000.00
Revenue This Year
$10.47
N/A
Revenue Next Year
$12.19
N/A
P/E Ratio
$51.16
N/A
Revenue Growth
12.99
N/A
52 Week Low
$38.48
$6.06
52 Week High
$63.75
$14.22

Technical Indicators

Market Signals
Indicator
SFST
ARVN
Relative Strength Index (RSI) 55.39 51.52
Support Level $53.96 N/A
Resistance Level $61.81 $10.18
Average True Range (ATR) 1.68 0.41
MACD -0.08 0.12
Stochastic Oscillator 50.43 61.62

Price Performance

Historical Comparison
SFST
ARVN

About SFST Southern First Bancshares Inc.

Southern First Bancshares Inc is a bank holding company. Through its banking subsidiary, it is engaged in the business of accepting demand deposits and savings deposits insured by the Federal Deposit Insurance Corporation (the FDIC), and providing commercial, consumer, and mortgage loans, ATM processing, and other banking products and services to the general public. The group operates through various retail offices located in the Greenville, Columbia, and Charleston markets of South Carolina, three retail offices in the Raleigh, Greensboro, and Charlotte markets of North Carolina, and one retail office in Atlanta, Georgia.

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Share on Social Networks: